Abstract
A clinical evaluation of phenylbutazone and Butapyrin® (a mixture of phenylbutazone and aminopyrine) was made in 409 patients who had a variety of rheumatic diseases. Preliminary European claims were substantiated.
In gout a specific favorable effect was brought about by phenylbutazone alone.
Effects equivalent to the previously reported favorable response to Butapyrin (Irgapyrin) were observed when its constituent phenylbutazone was used alone. The drug had a suppressive effect in a high percentage of patients with rheumatoid arthritis, ankylosing spondylitis, arthritis with psoriasis and mixed arthritis (rheumatoid arthritis plus osteoarthritis). Favorable effect in peritendinitis of the shoulders, osteoporosis of the spine and acute lumbosacral strain also was noted.
Toxicity resulted in discontinuance of medication in 10 per cent of patients with each drug. Manifestations of toxicity generally included fluid retention, nausea and rash, but there were several instances of transitory leukopenia and anemia. There was one instance of agranulocytosis with Butapyrin but none with phenylbutazone.† Aggravation of peptic ulcer occurred in ten patients with hemorrhage in two. Generally the toxicity was of a low order as compared with that of other drugs having an antirheumatic effect.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- FABRE J., MACH R. S. L'action de l'Irgapyrine sur les métabolismes du sel et de l'eau et sur les fonctions renales. Schweiz Med Wochenschr. 1951 May 19;81(20):473–477. [PubMed] [Google Scholar]
- FAHNDRICH W. H., JUNKERSDORF J. Vergleichende Untersuchungen zur parenteralen Pyramidontherapie, unter besonderer Berücksichtigung des chronischen Gelenkrheumatismus. Dtsch Med Wochenschr. 1950 Sep 1;75(35):1145–1148. doi: 10.1055/s-0028-1117633. [DOI] [PubMed] [Google Scholar]
- FENZ E. Wirkungsweise und neue Indikationen von Irgapyrin. Wien Med Wochenschr. 1950 Nov 25;100(45-46):754–756. [PubMed] [Google Scholar]
- JAQUES R., DOMENJOZ R. Histaminantagonistische Wirkung bei Pyrazolen und Antihistaminen. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1950;212(1-2):124–125. [PubMed] [Google Scholar]
- KIENLE H. Erfahrungsbericht über Irgapyrin Geigy ein neues, hochwirksames Injektionspräparat aus der Pyrazolreihe. Munch Med Wochenschr. 1950 Sep 1;92(21-22):885–889. [PubMed] [Google Scholar]
- STETTBACHER H. R. Zur Anwendung des injizierbaren Pyrazoloderivates Irgapyrin Geigy. Praxis. 1949 Dec 1;38(48):1069–1072. [PubMed] [Google Scholar]
- WILHELMI G., DOMENJOZ R. Vergleichende Untersuchungen über die Wirkung von Pyrazolen und Antihistaminen bei verschiedenen Arten der Experimentellen Entzündung. Arch Int Pharmacodyn Ther. 1951 Jan;85(1-2):129–143. [PubMed] [Google Scholar]
- WILHELMI G. Uber die antiphlogistische Wirkung von Pyrazolen, speziell von Irgapyrin, bei peroraler und parenteraler Verabreichung. Schweiz Med Wochenschr. 1950 Sep 2;80(35):936–942. [PubMed] [Google Scholar]